Our results support the hypothesis of BRAF- mutation independent activation of MAPK pathway leading to the development of resistance to BRAF inhibitor when treating BRAF-V600E mutated NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.